[go: up one dir, main page]

MXPA04006517A - Conjugados que comprenden un anticuerpo especifico para el dominio ed-b de fibronectina y sus usos para la deteccion y tratamiento de tumores. - Google Patents

Conjugados que comprenden un anticuerpo especifico para el dominio ed-b de fibronectina y sus usos para la deteccion y tratamiento de tumores.

Info

Publication number
MXPA04006517A
MXPA04006517A MXPA04006517A MXPA04006517A MXPA04006517A MX PA04006517 A MXPA04006517 A MX PA04006517A MX PA04006517 A MXPA04006517 A MX PA04006517A MX PA04006517 A MXPA04006517 A MX PA04006517A MX PA04006517 A MXPA04006517 A MX PA04006517A
Authority
MX
Mexico
Prior art keywords
tumours
fibronectin
treatment
domain
conjugates
Prior art date
Application number
MXPA04006517A
Other languages
English (en)
Inventor
Neri Giovanni
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of MXPA04006517A publication Critical patent/MXPA04006517A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invencion se refiere a metodos novedoso para diagnostico y tratamiento de tumores, utilizando peptidos novedosos para ligar radionuclidos.
MXPA04006517A 2002-01-03 2003-01-02 Conjugados que comprenden un anticuerpo especifico para el dominio ed-b de fibronectina y sus usos para la deteccion y tratamiento de tumores. MXPA04006517A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02000315 2002-01-03
US35870202P 2002-02-25 2002-02-25
PCT/EP2003/000009 WO2003055917A2 (en) 2002-01-03 2003-01-02 Conjugates comprising an antibody specific for the ed-b domain of fibronectin and their use for the detection and treatment of tumours

Publications (1)

Publication Number Publication Date
MXPA04006517A true MXPA04006517A (es) 2005-03-31

Family

ID=26077560

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04006517A MXPA04006517A (es) 2002-01-03 2003-01-02 Conjugados que comprenden un anticuerpo especifico para el dominio ed-b de fibronectina y sus usos para la deteccion y tratamiento de tumores.

Country Status (15)

Country Link
US (1) US20040001790A1 (es)
EP (2) EP1461360B1 (es)
JP (2) JP2005523887A (es)
CN (1) CN1612895B (es)
AU (1) AU2003210149B2 (es)
BR (1) BR0306715A (es)
CA (1) CA2468081A1 (es)
CY (1) CY1110923T1 (es)
HK (1) HK1076474A1 (es)
IL (2) IL162201A0 (es)
MX (1) MXPA04006517A (es)
NO (1) NO20043246L (es)
PL (1) PL369371A1 (es)
RU (1) RU2352582C2 (es)
WO (1) WO2003055917A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9610967D0 (en) * 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
US20030045681A1 (en) * 1998-05-11 2003-03-06 Anthony J. Zelano Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
US20030176663A1 (en) * 1998-05-11 2003-09-18 Eidgenossische Technische Hochscule Specific binding molecules for scintigraphy
WO2001062800A1 (en) 2000-02-24 2001-08-30 Eidgenössische Technische Hochschule Zürich Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
NZ524342A (en) * 2000-09-07 2005-09-30 Schering Ag Receptor in the EDb fibronectin domain
ATE452912T1 (de) * 2002-03-11 2010-01-15 Philogen Spa Antikörper aus anti-ed-b l19 gerichtet auf tumorblutgefässe
EP1514561A1 (en) * 2003-09-10 2005-03-16 Philogen S.p.A. Targeting of tumor vasculature using radiolabelled antibody L19 against fibronectin ED-B
DE10348319A1 (de) * 2003-10-17 2005-05-19 Schering Ag Bindemoleküle für die Extra-Domäne B von Fibronectin zur Detektion von atherosklerotischen Plaques
US20060039863A1 (en) * 2004-07-22 2006-02-23 Michael Schirner Use of cyanine dyes for the diagnosis of disease associated with angiogenesis
ATE374367T1 (de) * 2004-07-22 2007-10-15 Bayer Schering Pharma Ag Verwendung von cyanin-farbstoffen zur diagnose von krankheiten, welche mit angiogenese assoziert sind
US7785591B2 (en) 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
ES2291071B1 (es) * 2005-06-13 2009-03-16 Proyecto De Biomedicina Cima, S.L. Agentes y metodos basados en el uso del dominio eda de la fibronectina.
JP2009535372A (ja) * 2006-05-03 2009-10-01 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 抗ｅｄｂフィブロネクチンドメイン抗体ｌ１９−ｓｉｐ及び抗−ｅｇｆｒ−抗体の組合せ
BRPI0809989B8 (pt) * 2007-04-02 2021-05-25 Philogen Spa usos de um anticorpo ou fragmento de ligação a antígeno do mesmo que se liga a isoforma extradomínio-a (ed-a) de fibronectina e/ou ao ed-a de fibronectina
EP2036576A1 (en) * 2007-09-17 2009-03-18 Bayer Schering Pharma Aktiengesellschaft ED-B fibronectin as stratification marker for antitumor drugs
US8253725B2 (en) * 2007-12-28 2012-08-28 St. Jude Medical, Atrial Fibrillation Division, Inc. Method and system for generating surface models of geometric structures
EP2116555A1 (en) 2008-05-08 2009-11-11 Bayer Schering Pharma Aktiengesellschaft Use of a radioactively labelled molecule specifically binding to ED-B fibronectin in a method of treatment of Hodgkin lymphoma
JP5985392B2 (ja) * 2009-07-22 2016-09-06 アクティニウム ファーマシューティカルズ インコーポレイテッド 放射性免疫複合体を生成するための方法
WO2011078250A1 (ja) * 2009-12-25 2011-06-30 独立行政法人理化学研究所 生体内にて標的組織に指向する放射標識化合物およびその利用
WO2011110490A1 (en) 2010-03-09 2011-09-15 Bayer Pharma Aktiengesellschaft Process for the production of radioactively labelled scfv antibody fragments, kits and compositions
CN104215668A (zh) * 2014-08-25 2014-12-17 浙江大学 基于theed纤维阵列的二氧化碳传感器及其制备方法
US20180340936A1 (en) * 2015-11-16 2018-11-29 Hefei Lifeon Pharmaceutical Co. Ltd. Use of ed-b protein in diagnosis of tissue hyperplasia
BR112019007760A2 (pt) * 2016-10-17 2019-09-03 Pfizer anticorpos anti-edb e conjugados de anticorpo-fármaco
CA3155519A1 (en) * 2019-10-29 2021-05-06 Steve Shih-Lin Huang Psma-targeting imaging agents
PT4153232T (pt) 2020-05-22 2024-10-02 Philogen Spa Terapêutica com imunoconjugado de tnf-a para o tratamento de tumores cerebrais
AU2022310862A1 (en) 2021-07-14 2024-02-01 Regeneron Pharmaceuticals, Inc. Engineered t cell receptors fused to binding domains from antibodies
EP4504249A2 (en) 2022-04-08 2025-02-12 Regeneron Pharmaceuticals, Inc. Multipartite receptor and signaling complexes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0486622B1 (en) * 1989-08-09 1998-11-04 Rhomed, Incorporated Direct radiolabeling of antibodies and other proteins with technetium or rhenium
EP1997894B1 (en) * 1992-02-06 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Biosynthetic binding protein for cancer marker
GB9324807D0 (en) * 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
TWI259837B (en) * 1998-05-11 2006-08-11 Eidgenossische Tech Hochscule Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
US6171578B1 (en) * 1999-04-14 2001-01-09 Diatide, Inc. Benzodiazepine derivatives for imaging thrombi
CN1308347C (zh) * 1999-04-28 2007-04-04 德克萨斯大学董事会 用于通过选择性抑制vegf来治疗癌症的组合物和方法
WO2001062800A1 (en) 2000-02-24 2001-08-30 Eidgenössische Technische Hochschule Zürich Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis

Also Published As

Publication number Publication date
WO2003055917A2 (en) 2003-07-10
AU2003210149A1 (en) 2003-07-15
NO20043246L (no) 2004-08-02
IL162201A (en) 2011-04-28
EP1461360A2 (en) 2004-09-29
JP2005523887A (ja) 2005-08-11
RU2004123785A (ru) 2005-08-10
US20040001790A1 (en) 2004-01-01
HK1076474A1 (en) 2006-01-20
EP1461360B1 (en) 2010-08-18
IL162201A0 (en) 2005-11-20
JP4663020B2 (ja) 2011-03-30
EP2239274A1 (en) 2010-10-13
JP2009209149A (ja) 2009-09-17
CN1612895B (zh) 2010-05-12
BR0306715A (pt) 2004-12-28
CN1612895A (zh) 2005-05-04
CA2468081A1 (en) 2003-07-10
RU2352582C2 (ru) 2009-04-20
AU2003210149B2 (en) 2008-10-09
CY1110923T1 (el) 2015-06-10
WO2003055917A3 (en) 2003-12-24
PL369371A1 (en) 2005-04-18

Similar Documents

Publication Publication Date Title
MXPA04006517A (es) Conjugados que comprenden un anticuerpo especifico para el dominio ed-b de fibronectina y sus usos para la deteccion y tratamiento de tumores.
NO20060843L (no) RG1-antistoffer og anvendelser derav
RS80704A (en) ANTI- av?6.ANTIBODIES
IL244803B (en) Human anti-beta antibodies and their use
WO2005103081A3 (en) Human monoclonal antibodies against cd20
DK1553975T3 (da) Optimerede Fc-varianter og fremgangsmåder til generering heraf.
MX2007011064A (es) Anticuerpos contra cd38 para tratamiento de mieloma multiple.
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
SG170793A1 (en) Anti-mn antibodies and methods of using same
AU2003205077A1 (en) Imaging agents and methods of imaging naaladase of psma
MX2010007357A (es) Puesta de anti-cuerpos en objetivo mediante un dominio de reconocimiento modular.
EA201100923A1 (ru) Антитела человека против тканевого фактора
NZ605429A (en) Therapeutic human anti-il-1r1 monoclonal antibody
PT1644484E (pt) Células autólogas de indução de auto-tolerância de origem monocítica e sua utilização em preparações farmacêuticas
IL163902A0 (en) Antibodies against cancer antigen tmeff2 and uses thereof
WO2003104425A3 (en) NEW STABLE ANTI-CD22 ANTIBODIES
HK1074670A1 (en) Sets of digital antibodies directed against short epitopes, and methods using same
UA94211C2 (ru) Выделенное полностью человеческое моноклональное cd3 антитело
ATE277352T1 (de) Einetenascin-c isoform als marker für neoplasmen
WO2003106478A3 (en) ANTIBODIES BINDING TO ALPHAE INTEGRIN
SI1461360T1 (sl) Konjugati, ki obsegajo protitelo, specifično za domeno ED-B fibronektina, in njihova uporaba za detekcijo in zdravljenje tumorjev
ATE230761T1 (de) Monoklonale antikörper gegen einen komplex aus humanem act und einer serinprotease
EA202190387A1 (ru) Антитело к cd38 человека и его применение
CY1115000T1 (el) Ανθρωπινα αντισωματα εναντια στη λυσσα και χρησεις αυτων

Legal Events

Date Code Title Description
FG Grant or registration
HC Change of company name or juridical status